- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Clarivate Adds German Hospital Prescribing Insights to Solution
New data provides researchers with aggregated, anonymized specialty prescribing habits across brands and diseases.
Clarivate has released German hospital prescribing insights within The Clarivate Patient Data Intelligence (CPDI), which includes new aggregated, anonymized data product to provide clarity on this market’s trends, patient characteristics, and specialty prescribing habits across brands and diseases.
The self-service CPDI platform positions Clarivate as a leading provider of real-world data solutions in Europe, as well as providing pharma companies the ability to identify specialties they are most interested in and optimize commercial targeting in key European markets, including Italy, France, Spain and Germany.
Zoe Barker, Vice President of Product, Clarivate, said, in a press release, "Significant investment of resources is required to analyze real world data products, particularly to understand the European market landscape, patient behavior, and prescribing habits. Such investment can delay the success of drug launches. With the addition of German hospital prescribing insights, Clarivate continues to deliver market leading intelligence that empowers life science and healthcare organizations to create a healthier tomorrow."
Reference: Clarivate Enhances Patient Data Intelligence Solution with Addition of German Hospital Prescribing Insights. London, July 27, 2023 /PRNewswire.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
